Is Catalyst Pharmaceuticals (CPRX) Pricing Look Interesting After Recent Share Price Pullback?

Simply Wall St.

Mar 23

If you are wondering whether Catalyst Pharmaceuticals at around US$22.79 is priced high, low, or just about fair, this article breaks down what the current tag might really mean for you. The stock has...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2621777875"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621777875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621777875?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-23 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621777875","market":"hk","top_or_hot":-1,"title":"Is Catalyst Pharmaceuticals (CPRX) Pricing Look Interesting After Recent Share Price Pullback?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Catalyst Pharmaceuticals at around US$22.79 is priced high, low, or just about fair, this article breaks down what the current tag might really mean for you. The stock has...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/is-catalyst-pharmaceuticals-cprx-pricing-look-interesting-af\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Catalyst Pharmaceuticals (CPRX) Pricing Look Interesting After Recent Share Price Pullback?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Catalyst Pharmaceuticals (CPRX) Pricing Look Interesting After Recent Share Price Pullback?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 17:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/is-catalyst-pharmaceuticals-cprx-pricing-look-interesting-af><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Catalyst Pharmaceuticals at around US$22.79 is priced high, low, or just about fair, this article breaks down what the current tag might really mean for you. The stock has...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/is-catalyst-pharmaceuticals-cprx-pricing-look-interesting-af\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/is-catalyst-pharmaceuticals-cprx-pricing-look-interesting-af","article_id":"2621777875","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/is-catalyst-pharmaceuticals-cprx-pricing-look-interesting-af","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621777875","pubTimestamp":1774256708,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Catalyst Pharmaceuticals at around US$22.79 is priced high, low, or just about fair, this article breaks down what the current tag might really mean for you.\nThe stock has seen mixed returns, with a 2.2% decline over the last week, a 6.2% decline over the last month, a 1.6% decline year to date, but a 38.6% gain over 3 years and a very large gain over 5 years.\nRecent coverage has focused on how this biopharma name fits into investors’ watchlists, with attention...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","CPRX":"Catalyst Pharmaceutical Partners","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D"},"translate_title":"在最近股价回调后，Catalyst Pharmaceuticals(CPRX)的定价看起来有趣吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1.5,"DCF":1},"content_text":"If you are wondering whether Catalyst Pharmaceuticals at around US$22.79 is priced high, low, or just about fair, this article breaks down what the current tag might really mean for you. The stock has seen mixed returns, with a 2.2% decline over the last week, a 6.2% decline over the last month, a 1.6% decline year to date, but a 38.6% gain over 3 years and a very large gain over 5 years. Recent coverage has focused on how this biopharma name fits into investors’ watchlists, with attention on its long run share price record and how that aligns with expectations for its business. This context helps explain why some investors are rechecking whether the recent 11.5% 1 year decline signals changing risk sentiment or just normal volatility after strong multi year returns. Catalyst Pharmaceuticals currently has a valuation score of 6 out of 6. Next, the article will compare different valuation approaches to see how that score stacks up, before finishing with a broader framework that can help you judge whether any valuation result really fits your own view.  Find out why Catalyst Pharmaceuticals's -11.5% return over the last year is lagging behind its peers. AdvertisementApproach 1: Catalyst Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future cash flows and discounting them back to today, so you can compare that value with the current share price. For Catalyst Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in US$. The latest twelve month free cash flow sits at about $129.4 million. Analysts provide free cash flow estimates out to 2030, with Simply Wall St extrapolating beyond the initial analyst horizon to build a ten year path, including a projected free cash flow of $340 million in 2030. After discounting these projected cash flows, the model arrives at an estimated intrinsic value of about $63.46 per share. Compared with the recent share price near $22.79, this implies an intrinsic discount of roughly 64.1%, which points to the shares trading at a substantial markdown relative to this cash flow based estimate. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Catalyst Pharmaceuticals is undervalued by 64.1%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks. CPRX Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Catalyst Pharmaceuticals. Approach 2: Catalyst Pharmaceuticals Price vs Earnings For established, profitable companies, the P/E ratio is often a useful yardstick because it links what you pay directly to the earnings the business is already generating. A higher P/E usually reflects higher growth expectations or lower perceived risk, while a lower P/E can signal more modest growth expectations or higher perceived risk. Catalyst Pharmaceuticals currently trades on a P/E of 13.0x. That sits below the Biotechs industry average of about 16.7x and also below the peer group average of 19.9x. On those simple comparisons alone, the shares are on a lower earnings multiple than many similar names. Simply Wall St also calculates a proprietary “Fair Ratio” of 16.0x for Catalyst Pharmaceuticals. This is designed to be a more tailored benchmark than a plain industry or peer comparison because it factors in elements such as earnings growth, profit margins, risk profile, industry, and market capitalization. By comparing the current P/E of 13.0x with this Fair Ratio of 16.0x, the stock screens as undervalued on this earnings based approach. Result: UNDERVALUED NasdaqCM:CPRX P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your Catalyst Pharmaceuticals Narrative Earlier, it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to put a clear story behind the numbers by linking your view on Catalyst Pharmaceuticals future revenue, earnings and margins to a financial forecast and a fair value estimate that sits alongside the current share price on Simply Wall St's Community page. There, millions of investors share their perspectives, so you can quickly see, for example, one investor building a bullish story around expanding rare disease diagnoses, durable margins and the US$40 analyst target, while another focuses on concentration in FIRDAPSE, patent and generic risks and aligns more closely with the US$31 target. You can then use those different fair values versus the current price to decide whether the stock looks appealing, expensive or somewhere in between, with each Narrative updating automatically as new earnings, news or guidance come through. Do you think there's more to the story for Catalyst Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqCM:CPRX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}